Home / Journals / ECN / Vol.35, No.1, 2024
Special Issues
  • Open AccessOpen Access

    REVIEW

    Identification of inflammatory markers as indicators for disease progression in primary Sjögren syndrome

    Yan Li1,2,3,#, Jimin Zhang1,2,3,#, Xiaoyan Liu4, Kumar Ganesan5, Guixiu Shi1,2,3
    European Cytokine Network, Vol.35, No.1, pp. 1-12, 2024, DOI:10.1684/ecn.2024.0496
    Abstract Primary Sjögren syndrome (pSS) is a systemic autoimmune disorder that affects various systems in the body, resulting in symptoms such as dry eyes and mouth, pain, and fatigue. Inflammation plays a critical role in pSS and its associated complications, with chronic inflammation being a common occurrence in patients with pSS. This review of the literature highlights inflammatory markers that could serve as indicators to predict disease progression in pSS. Results: Laboratory markers are frequently and significantly increased in pSS patients, including erythrocyte sedimentation rate, C-reactive protein, complement proteins, S100 proteins, cytokines (IFNs, CD40 ligand, soluble CD25, More >

  • Open AccessOpen Access

    ARTICLE

    Cytokine fingerprint differences following infection and vaccination – what can we learn from COVID-19?

    Shira Cohen Rubin1,*, Nadav Zacks1, Ori Wand2, Ophir Freund3, Evgeni Gershman3, Anna Breslavsky2, Rotem Givoli-Vilensky1, Anat Tzurel Ferber2, Natalya Bilenko1,4, Amir Bar-Shai3
    European Cytokine Network, Vol.35, No.1, pp. 13-19, 2024, DOI:10.1684/ecn.2024.0494
    Abstract COVID-19 vaccination and acute infection result in cellular and humoral immune responses with various degrees of protection. While most studies have addressed the difference in humoral response between vaccination and acute infection, studies on the cellular response are scarce. We aimed to evaluate differences in immune response among vaccinated patients versus those who had recovered from COVID-19. Materials and Methods: This was a prospective study in a tertiary medical centre. The vaccinated group included health care workers, who had received a second dose of the BNT162b2 vaccine 30 days ago. The recovered group included adults… More >

Per Page:

Share Link